半乳糖凝集素-1 与脑癌的免疫治疗。

Galectin-1 and immunotherapy for brain cancer.

机构信息

Laboratory of Experimental Immunology, Catholic University Leuven, Leuven, Belgium.

出版信息

Expert Rev Neurother. 2011 Apr;11(4):533-43. doi: 10.1586/ern.11.40.

DOI:10.1586/ern.11.40

Abstract

The prognosis of patients diagnosed with high-grade glioma continues to be dismal in spite of multimodal treatment. Active specific immunotherapy by means of dendritic cell vaccination is considered to be a new promising concept that aims at generating an anti-tumoral immune response. However, it is now widely accepted that the success of immunotherapeutic strategies to promote tumor regression will rely not only on enhancing the effector arm of the immune response but also on downregulation of the counteracting tolerogenic signals. In this article, we summarize evidence that galectin-1, an evolutionarily conserved glycan-binding protein that is abundantly expressed in high-grade glioma, is an important player in glioma-mediated immune escape.

摘要

尽管采用了多模式治疗，高等级神经胶质瘤患者的预后仍然不容乐观。通过树突细胞疫苗进行主动特异性免疫治疗被认为是一种新的有前途的概念，旨在产生抗肿瘤免疫反应。然而，现在人们普遍认为，免疫治疗策略促进肿瘤消退的成功不仅依赖于增强免疫反应的效应器臂，还依赖于下调对抗性耐受信号。在本文中，我们总结了证据表明，半乳糖凝集素-1 是一种在高等级神经胶质瘤中大量表达的进化上保守的聚糖结合蛋白，是神经胶质瘤介导的免疫逃避中的一个重要因素。